Targeting interleukin-4 in asthma: Lost in translation?

American Journal of Respiratory Cell and Molecular Biology

Volumn 47, Issue 3, 2012, Pages 261-270

  Maes, Tania ^a   Joos, Guy F ^a   Brusselle, Guy G ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Asthma; Asthma heterogeneity; Interleukin 4; Murine models; Targeted therapy

Indexed keywords

AIR 345; AIR 645; ALTRAKINCEPT; AMG 317; ANRUKINZUMAB; ANTIASTHMATIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ASI 517499; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYTOKINE RECEPTOR ANTAGONIST; IMA 026; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4 RECEPTOR ANTAGONIST; INTERLEUKIN 5; LEBRIKIZUMAB; PASCOLIZUMAB; PITRAKINRA; PLACEBO; SMALL INTERFERING RNA; STAT6 PROTEIN; TRALOKINUMAB; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ANTISENSE THERAPY; ASTHMA; CD4+ T LYMPHOCYTE; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH2 CELL;

ANIMALS; ASTHMA; HUMANS; HYPERSENSITIVITY; INTERLEUKIN-4; MALE; MICE; SIGNAL TRANSDUCTION;

ANIMALIA; MURINAE;

EID: 84864292663     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0080TR     Document Type: Review

References (119)

1. Global Inititative for Asthma and (accessed February 17, 2012). Available from: http://www.ginasthma.com.
2. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008;8:218-230. (Pubitemid 351323290)
3. Steinke JW, Borish L. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res 2001;2:66-70. (Pubitemid 34187909)
4. Daher S, Santos LM, Sole D, De Lima MG, Naspitz CK, Musatti CC. Interleukin-4 and soluble CD23 serum levels in asthmatic atopic children. J Investig Allergol Clin Immunol 1995;5:251-254.
5. Walker C, Bauer W, Braun RK, Menz G, Braun P, Schwarz F, Hansel TT, Villiger B. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med 1994;150:1038-1048. (Pubitemid 24318033)
6. Humbert M, Durham SR, Ying S, Kimmitt P, Barkans J, Assoufi B, Pfister R, Menz G, Robinson DS, Kay AB, et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 1996; 154:1497-1504. (Pubitemid 26391204)
7. Kotsimbos TC, Ernst P, Hamid QA. Interleukin-13 and interleukin-4 are coexpressed in atopic asthma. Proc Assoc Am Physicians 1996; 108:368-373.
8. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304.
9. Ying S, Durham SR, Corrigan CJ, Hamid Q, Kay AB. Phenotype of cells expressing mRNA for TH2-type (interleukin 4 and interleukin 5) and TH1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol 1995;12:477-487.
10. Ying S, Humbert M, Barkans J, Corrigan CJ, Pfister R, Menz G, Larche M, Robinson DS, Durham SR, Kay AB. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1997;158:3539-3544. (Pubitemid 127484076)
11. Kotsimbos TC, Ghaffar O, Minshall EM, Humbert M, Durham SR, Pfister R, Menz G, Kay AB, Hamid QA. Expression of the IL-4 receptor alpha-subunit is increased in bronchial biopsy specimens from atopic and nonatopic asthmatic subjects. J Allergy Clin Immunol 1998;102:859-866. (Pubitemid 28543539)
12. Mullings RE, Wilson SJ, Puddicombe SM, Lordan JL, Bucchieri F, Djukanovic R, Howarth PH, Harper S, Holgate ST, Davies DE. Signal transducer and activator of transcription 6 (STAT-6) expression and function in asthmatic bronchial epithelium. J Allergy Clin Immunol 2001;108:832-838. (Pubitemid 33096218)
13. Taha R, Hamid Q, Cameron L, Olivenstein R. T helper type 2 cytokine receptors and associated transcription factors GATA-3, c-MAF, and signal transducer and activator of transcription factor-6 in induced sputum of atopic asthmatic patients. Chest 2003;123:2074-2082. (Pubitemid 36706735)
14. Kroegel C, Julius P, Matthys H, Virchow JC Jr, Luttmann W. Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur Respir J 1996;9:899-904. (Pubitemid 26191632)
15. Batra V, Musani AI, Hastie AT, Khurana S, Carpenter KA, Zangrilli JG, Peters SP. Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)-beta1, TGF-beta2, interleukin (IL)-4 and IL-13 after segmental allergen challenge and their effects on alpha-smooth muscle actin and collagen III synthesis by primary human lung fibroblasts. Clin Exp Allergy 2004;34:437-444. (Pubitemid 38373007)
16. Leonard C, Tormey V, Burke C, Poulter LW. Allergen-induced cytokine production in atopic disease and its relationship to disease severity. Am J Respir Cell Mol Biol 1997;17:368-375. (Pubitemid 127500842)
17. Shi HZ, Deng JM, Xu H, Nong ZX, Xiao CQ, Liu ZM, Qin SM, Jiang HX, Liu GN, Chen YQ. Effect of inhaled interleukin-4 on airway hyperreactivity in asthmatics. Am J Respir Crit Care Med 1998;157:1818-1821.
18. Weiss ST, Raby BA, Rogers A. Asthma genetics and genomics 2009. Curr Opin Genet Dev 2009;19:279-282.
19. Michel S, Liang L, Depner M, Klopp N, Ruether A, Kumar A, Schedel M, Vogelberg C, von Mutius E, von Berg A, et al. Unifying candidate gene and GWAS approaches in asthma. PLoS ONE 2010;5:e13894.
20. Brusselle GG, Kips JC, Tavernier JH, van der Heyden JG, Cuvelier CA, Pauwels RA, Bluethmann H. Attenuation of allergic airway inflammation in IL-4 deficient mice. Clin Exp Allergy 1994;24:73-80. (Pubitemid 24210819)
21. Brusselle G, Kips J, Joos G, Bluethmann H, Pauwels R. Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. Am J Respir CellMol Biol 1995;12:254-259.
22. Chatila TA. Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol Med 2004;10:493-499. (Pubitemid 39303622)
23. Chatila TA, Li N, Garcia-Lloret M, Kim HJ, Nel AE. T-cell effector pathways in allergic diseases: transcriptional mechanisms and therapeutic targets. J Allergy Clin Immunol 2008;121:812-823. (Pubitemid 351458502)
24. Schleimer RP, Sterbinsky SA, Kaiser J, Bickel CA, Klunk DA, Tomioka K, Newman W, Luscinskas FW, Gimbrone MA Jr, McIntyre BW. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol 1992;148:1086-1092.
25. Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 1995;154:799-803.
26. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-2261. (Pubitemid 29004074)
27. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998;282:2261-2263. (Pubitemid 29004075)
28. Lewis CC, Aronow B, Hutton J, Santeliz J, Dienger K, Herman N, Finkelman FD, Wills-Karp M. Unique and overlapping gene expression patterns driven by IL-4 and IL-13 in the mouse lung. J Allergy Clin Immunol 2009;123:795-804.
29. Perkins C, Wills-Karp M, Finkelman FD. IL-4 induces IL-13-independent allergic airway inflammation. J Allergy Clin Immunol 2006;118: 410-419. (Pubitemid 44142729)
30. Finkelman FD, Hogan SP, Hershey GK, Rothenberg ME, Wills-Karp M. Importance of cytokines in murine allergic airway disease and human asthma. J Immunol 2010;184:1663-1674.
31. Corry DB, Folkesson HG, Warnock ML, Erle DJ, Matthay MA, Wiener-Kronish JP, Locksley RM. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 1996;183:109-117. (Pubitemid 26028750)
32. Park SJ, Lee YC. Interleukin-17 regulation: an attractive therapeutic approach for asthma. Respir Res 2010;11:78.
33. Gessner A, Mohrs K, Mohrs M. Mast cells, basophils, and eosinophils acquire constitutive IL-4 and IL-13 transcripts during lineage differentiation that are sufficient for rapid cytokine production. J Immunol 2005;174:1063-1072. (Pubitemid 40094303)
34. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, Heusser CH, Howarth PH, Holgate ST. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994;10:471-480.
35. Nonaka M, Nonaka R, Woolley K, Adelroth E, Miura K, Okhawara Y, Glibetic M, Nakano K, O'Byrne P, Dolovich J, et al. Distinct immunohistochemical localization of IL-4 in human inflamed airway tissues. IL-4 is localized to eosinophils in vivo and is released by peripheral blood eosinophils. J Immunol 1995;155:3234-3244.
36. Pouliot P, Turmel V, Gelinas E, Laviolette M, Bissonnette EY. Interleukin-4 production by human alveolar macrophages. Clin Exp Allergy 2005;35:804-810. (Pubitemid 40961355)
37. Andrews R, Rosa L, Daines M, Khurana HG. Reconstitution of a functional human type II IL-4/IL-13 receptor in mouse B cells: demonstration of species specificity. J Immunol 2001;166:1716-1722. (Pubitemid 32114655)
38. Dubois GR, Schweizer RC, Versluis C, Bruijnzeel-Koomen CA, Bruijnzeel PL. Human eosinophils constitutively express a functional interleukin-4 receptor: interleukin-4 -induced priming of chemotactic responses and induction of PI-3 kinase activity. Am J Respir Cell Mol Biol 1998;19:691-699. (Pubitemid 128354252)
39. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C, Azzarone B. Interleukin (IL) 4 and IL-13 act on human lung fibroblasts: implication in asthma. J Clin Invest 1998;101:2129- 2139.
40. van der Velden V, Naber BA, Wierenga-Wolf AF, Debets R, Savelkoul HF, Overbeek SE, Hoogsteden HC, Versnel MA. Interleukin 4 receptors on human bronchial epithelial cells: an in vivo and in vitro analysis of expression and function. Cytokine 1998;10:803-813. (Pubitemid 28495233)
41. Siddiqui S, Mistry V, Doe C, Stinson S, Foster M, Brightling C. Airway wall expression of OX40/OX40L and interleukin-4 in asthma. Chest 2010;137:797-804.
42. LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, Keegan AD, Garcia KC. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 2008;132:259-272. (Pubitemid 351172435)
43. Kelly-Welch AE, Melo ME, Smith E, Ford AQ, Haudenschild C, Noben-Trauth N, Keegan AD. Complex role of the IL-4 receptor alpha in a murine model of airway inflammation: expression of the IL-4 receptor alpha on nonlymphoid cells of bone marrow origin contributes to severity of inflammation. J Immunol 2004;172: 4545-4555. (Pubitemid 38375272)
44. Kuperman DA, Schleimer RP. Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. Curr Mol Med 2008;8:384-392.
45. Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, Zhu Z, Elias JA, Sheppard D, Erle DJ. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002;8:885-889.
46. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010;19:46-54.
47. Blease K, Schuh JM, Jakubzick C, Lukacs NW, Kunkel SL, Joshi BH, Puri RK, Kaplan MH, Hogaboam CM. Stat6-deficient mice develop airway hyperresponsiveness and peribronchial fibrosis during chronic fungal asthma. Am J Pathol 2002;160:481-490. (Pubitemid 34160325)
48. Renz H, Bradley K, Enssle K, Loader JE, Larsen GL, Gelfand EW. Prevention of the development of immediate hypersensitivity and airway hyperresponsiveness following in vivo treatment with soluble IL-4 receptor. Int Arch Allergy Immunol 1996;109:167-176. (Pubitemid 26029384)
49. Henderson WR Jr, Chi EY, Maliszewski CR. Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. J Immunol 2000;164:1086-1095. (Pubitemid 30043738)
50. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L. Interleukin-4 receptor in moderate atopic asthma: a phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999;160:1816-1823. (Pubitemid 30004681)
51. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, Agosti JM. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001;107:963-970. (Pubitemid 32523334)
52. Immunex. Phase II efficacy study of aerosolized recombinant human IL-4 receptor in asthma (accessed December 6, 2011). Available from: http://clinicaltrials.gov/ct2/show/study/NCT00017693.
53. Steinke JW. Anti-interleukin-4 therapy. Immunol Allergy Clin North Am 2004;24:599-614. (Pubitemid 39330309)
54. NIAID. Phase II efficacy study of aerosolized recombinant human IL-4 receptor in asthma (accessed December 6, 2011). Available from: http://clinicaltrials.gov/ct2/show/NCT00001909.
55. Andrews AL, Holloway JW, Holgate ST, Davies DE. IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets. J Immunol 2006;176:7456-7461. (Pubitemid 43849048)
56. Zhou CY, Crocker IC, Koenig G, Romero FA, Townley RG. Anti-interleukin- 4 inhibits immunoglobulin E production in a murine model of atopic asthma. J Asthma 1997;34:195-201. (Pubitemid 27270453)
57. Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia- Amirhosseini P, Cook RM. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002;130:93-100.
58. Shames RS, Vexler V, Lane N, McClellan M, Shi J, Keller S, Young DY, Nieman RB, Hart T. The safety and pharmacokinetics of SB240683 (anti-IL-4 humanized monoclonal antibody) in patients with mild to moderate asthma [abstract]. J Allergy Clin Immunol 2001;163:A523.
59. PDL BioPharma, Inc. Pilot study in patients with symptomatic steroidnaive asthma (accessed December 6, 2011). Available from: http:// clinicaltrials.gov/ct2/show/NCT00024544.
60. Popescu FD, Popescu F. A review of antisense therapeutic interventions for molecular biological targets in asthma. Biologics 2007;1:271-283.
61. Maes T, Tournoy KG, Joos GF. Gene therapy for allergic airway diseases. Curr Allergy Asthma Rep 2011;11:163-172.
62. Cao Y, Zeng D, Song Q, Cao C, Xie M, Liu X, Xiong S, Xu Y, Xiong W. The effects of antisense interleukin-4 gene transferred by recombinant adeno-associated virus vector on the airway remodeling in allergic rats. J Asthma 2010;47:951-958.
63. Yang G, Volk A, Petley T, Emmell E, Giles-Komar J, Shang X, Li J, Das AM, Shealy D, Griswold DE, et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 2004;28:224-232. (Pubitemid 39573497)
64. Tomlinson KL, Davies GC, Sutton DJ, Palframan RT. Neutralisation of interleukin-13 in mice prevents airway pathology caused by chronic exposure to house dust mite. PLoS ONE 2010;5:e13136.
65. Bree A, Schlerman FJ, Wadanoli M, Tchistiakova L, Marquette K, Tan XY, Jacobson BA, Widom A, Cook TA, Wood N, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol 2007;119:1251-1257. (Pubitemid 46654187)
66. Vugmeyster Y, Szklut P, Tchistiakova L, Abraham W, Kasaian M, Xu X. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. Int Immunopharmacol 2008;8:477-483.
67. Martin PL, Fisher D, Glass W, O'Neil K, Das A, Martin EC, Li L. Preclinical safety and pharmacology of an anti-human interleukin-13 monoclonal antibody in normal macaques and in macaques with allergic asthma. Int J Toxicol 2008;27:351-358. (Pubitemid 352767914)
68. Kasaian MT, Donaldson DD, Tchistiakova L, Marquette K, Tan XY, Ahmed A, Jacobson BA, Widom A, Cook TA, Xu X, et al. Efficacy of IL-13 neutralization in a sheep model of experimental asthma. Am J Respir Cell Mol Biol 2007;36:368-376. (Pubitemid 46365288)
69. Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, Deschesnes F, Duong M, Durn BL, Howie KJ, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011; 183:1007-1014.
70. Wyeth (Pfizer). Study evaluating the effect of IMA-026 on allergeninduced late asthma response in mild asthma (accessed February 9, 2012). Available from: http://clinicaltrials.gov/ct2/show/NCT00725582.
71. Wyeth (Pfizer). Study evaluating the effects of IMA-638 on allergeninduced airway responses in subjects with mild atopic asthma (accessed February 9, 2012). Available from: http://clinicaltrials.gov/ ct2/show/NCT00410280.
72. Kasaian MT, Raible D, Marquette K, Cook TA, Zhou S, Tan XY, Tchistiakova L. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Ralpha2. J Immunol 2011; 187:561-569.
73. Wyeth (Pfizer). Study evaluating the effect of IMA-638 in Subjects with persistent asthma (accessed February 9, 2012). Available from: http://clinicaltrials.gov/ct2/show/NCT00425061.
74. Genentech. A study to evaluate MILR1444A in the prevention of allergen-induced airway obstruction in adults with mild allergic asthma (accessed February 9, 2012). Available from: http://clinicaltrials.gov/ ct2/show/NCT00781443.
75. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365: 1088-1098.
76. Genentech. A study of lebrikizumab (MILR1444A) in adult patients with asthma who are inadequately controlled on inhaled corticosteroids (MILLY) (accessed February 9, 2012). Available from: http://clinicaltrials.gov/ct2/show/ NCT00930163.
77. Genentech. A study to evaluate lebrikizumab (MILR1444A) in adult patients with asthma who are not taking inhaled corticosteroids (MOLLY) (accessed February 9, 2012). Available from: http:// clinicaltrials.gov/ct2/show/ NCT00971035.
78. May R, Monk P, Cohen E, Manuel D, Dempsey F, Davis N, Dodd A, Corkill D, Woods J, Joberty-Candotti C, et al. Preclinical development of CAT-354, an IL-13-neutralising antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol 2011;166:177-193.
79. Walsh GM. Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD. Curr Opin Investig Drugs 2010;11:1305-1312.
80. Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm Med 2010;10:3.
81. Medimmune. A study to assess the safety and tolerability of multiple doses of multi-level of a drug in subjects with moderate asthma (accessed February 9, 2012). Available from: http://clinicaltrials.gov/ ct2/show/NCT00974675.
82. Medimmune. A Phase 2b, randomized, double-blind study to evaluate the efficacy of tralokinumab in adults with asthma (accessed February 9, 2012). Available from: http://clinicaltrials.gov/ct2/show/ NCT01402986.
83. Medimmune. Study to evaluate the safety and efficacy of CAT-354 (accessed February 9, 2012). Available from: http://clinicaltrials. gov/ct2/show/ NCT00873860.
84. Tomkinson A, Duez C, Cieslewicz G, Pratt JC, Joetham A, Shanafelt MC, Gundel R, Gelfand EW. A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J Immunol 2001;166:5792-5800. (Pubitemid 32374206)
85. Hahn C, Teufel M, Herz U, Renz H, Erb KJ, Wohlleben G, Brocker EB, Duschl A, Sebald W, Grunewald SM. Inhibition of the IL-4/IL- 13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma. J Allergy Clin Immunol 2003;111:1361-1369. (Pubitemid 36683693)
86. Tian D, Fu Z, Liu E, He Y, Wang X, Wang L. Therapeutic effect of intratracheal administration of murine IL-4 receptor antagonist on asthmatic airway inflammation. J Asthma 2008;45:715-721.
87. Tomkinson A, Tepper J, Morton M, Bowden A, Stevens L, Harris P, Lindell D, Fitch N, Gundel R, Getz EB. Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma. Allergy 2010;65:69-77.
88. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370:1422-1431. (Pubitemid 47576168)
89. Aerovance, Inc. A Phase IIa study of subcutaneous AER 001 on antigen challenge in atopic asthmatic subjects (28 day study) (accessed December 6, 2011). Available from: http://clinicaltrials.gov/ct2/show/ NCT00535028.
90. Aerovance, Inc. Effects of AER 001 administered by nebulization on antigen challenge in atopic asthmatics (accessed December 6, 2011). Available from: http://clinicaltrials.gov/ct2/show/NCT00535431.
91. Antoniu SA, Cojocaru I. Pitrakinra for asthma. Expert Opin Biol Ther 2010;10:1609-1615.
92. Burmeister GE, Fisher DM, Fuller R. Human pharmacokinetics/ pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J Clin Pharmacol 2009;49:1025-1036.
93. Aerovance Inc. Press release. Phase 2b clinical trial results show Aerovance's aerovanttm is effective in patients with eosinophilic asthma: statistically significant results support novel inhaled IL-4/IL- 13 inhibitor's continued clinical development. Berkeley: Aerovance; 2010. Available from: www.aerovance.com/news/press-releases/.
94. Aerovance, Inc. A study of the treatment-sparing effects of AEROVANT AER 001 inhalation powder in asthma patients, AEROTRIAL (accessed December 6, 2011). Available from: http://clinicaltrials.gov/ ct2/show/NCT00801853.
95. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-984.
96. Zhou B, Headley MB, Aye T, Tocker J, Comeau MR, Ziegler SF. Reversal of thymic stromal lymphopoietin-induced airway inflammation through inhibition of Th2 responses. J Immunol 2008;181:6557-6562.
97. Kakkar T, Sung C, Gibiansky L, Vu T, Narayanan A, Lin SL, Vincent M, Banfield C, Colbert A, Hoofring S, et al. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res 2011;28:2530-2542.
98. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, Wenzel SE, Chon Y, Dunn M, Weng HH, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010;181:788-796.
99. Amgen Inc. Phase II study to evaluate the efficacy of AMG 317 (accessed December 6, 2011). Available from: http://clinicaltrials. gov/ct2/show/ NCT00436670.
100. Karras JG, Crosby JR, Guha M, Tung D, Miller DA, Gaarde WA, Geary RS, Monia BP, Gregory SA. Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice. Am J Respir Cell Mol Biol 2007;36:276-285. (Pubitemid 46365278)
101. Altair Therapeutics, Inc. A Phase 1 study of AIR645 in healthy subjects and subjects with controlled asthma (AIR645-CS1) (accessed December 6, 2011). Available from: http://clinicaltrials.gov/ct2/show/ NCT00658749.
102. Seguin RM, Ferrari N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2009;18:1505-1517.
103. Altair Therapeutics, Inc. Study evaluating the effects of AIR645 on allergen-induced airway responses in subjects with mild atopic asthma (accessed December 6, 2011). Available from: http:// clinicaltrials.gov/ct2/show/ NCT00941577.
104. McCusker CT, Wang Y, Shan J, Kinyanjui MW, Villeneuve A, Michael H, Fixman ED. Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide. J Immunol 2007;179:2556-2564.
105. Chiba Y, TodorokiM, Nishida Y, Tanabe M, Misawa M. A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. Am J Respir Cell Mol Biol 2009;41:516-524.
106. Darcan-Nicolaisen Y, Meinicke H, Fels G, Hegend O, Haberland A, Kuhl A, Loddenkemper C, Witzenrath M, Kube S, Henke W, et al. Small interfering RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice. J Immunol 2009;182:7501-7508.
107. Tian XR, Tian XL, Bo JP, Li SG, Liu ZL, Niu B. Inhibition of allergic airway inflammation by antisense-induced blockade of STAT6 expression. Chin Med J (Engl) 2011;124:26-31.
108. Walker W, Healey GD, Hopkin JM. RNA interference of STAT6 rapidly attenuates ongoing interleukin-13-mediated events in lung epithelial cells. Immunology 2009;127:256-266.
109. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836-844. (Pubitemid 39346477)
110. Paul WE. What determines Th2 differentiation, in vitro and in vivo? Immunol Cell Biol 2010;88:236-239.
111. Forbes E, van Panhuys N, Min B, Le Gros G. Differential requirements for IL-4/STAT6 signalling in CD4 T-cell fate determination and Th2- immune effector responses. Immunol Cell Biol 2010;88:240-243.
112. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172:2731-2738. (Pubitemid 38263654)
113. Zosky GR, Sly PD. Animal models of asthma. Clin Exp Allergy 2007; 37:973-988. (Pubitemid 46955517)
114. Finkelman FD, Wills-Karp M. Usefulness and optimization of mouse models of allergic airway disease. J Allergy Clin Immunol 2008;121: 603-606. (Pubitemid 351323871)
115. Wenzel S, Holgate ST. The mouse trap: it still yields few answers in asthma. Am J Respir Crit Care Med 2006;174:1173-1176. (Pubitemid 44924815)
116. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388-395.
117. Bhakta NR, Woodruff PG. Human asthma phenotypes: from the clinic, to cytokines, and back again. Immunol Rev 2011;242:220-232.
118. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D'Agostino R Jr, Castro M, Curran-Everett D, Fitzpatrick AM, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181:315-323.
119. Maes T, Provoost S, Lanckacker EA, Cataldo DD, Vanoirbeek JA, Nemery B, Tournoy KG, Joos GF. Mouse models to unravel the role of inhaled pollutants on allergic sensitization and airway inflammation. Respir Res 2010;11:7.